An Introduction to Neuro-Oncology
Neuro-oncology is a rapidly evolving field, encompassing the diagnosis and management of primary and metastatic tumours of the central nervous system and complications of systemic cancers or cancer treatment. Advances in neuroimaging have allowed accurate screening for intracranial disease at initial cancer diagnosis, precise targeting of intracranial lesions during treatment and differentiation of treatment effects from disease progression by incorporating functional imaging. Other recent advances include tumour treating fields; hippocampal avoidance whole-brain radiotherapy (WBRT); WBRT with memantine; use of artificial intelligence together with stereotactic radiotherapy; and systemically delivered immunotherapies, including vaccines and immune checkpoint inhibitors.
Expert video highlights and insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the ever-changing landscape.
Primary Central Nervous System Anaplastic Large Cell Lymphoma is an Unusual Brain Tumour
European Oncology & Haematology, 2014;10(1):48–50 DOI: https://doi.org/10.17925/EOH.2014.10.1.48
Case Presentation A 64-year-old male presented with a 1-month history of progressively worsening headaches. He had no other central neurological symptoms, including ocular symptoms, and examination of the central and peripheral nervous system was normal. Physical examination did not reveal lymphadenopathy or organomegaly and was normal for all systems examined. No constitutional symptoms such as […]
Could Metabolic Therapy Become a Viable Alternative to the Standard of Care for Managing Glioblastoma?
Oncology & Hematology Review, 2014;10(1):13–20 DOI: https://doi.org/10.17925/OHR.2014.10.1.13
Glioblastoma Multiforme Glioblastoma multiforme (GBM) is the most malignant of the primary brain cancers with only about 12 % of patients surviving beyond 36 months (longterm survivors).1–4 Most GBMs are heterogeneous in cellular composition consisting of tumor stem cells, malignantly transformed mesenchymal cells, and host stromal cells; hence, the name ‘glioblastoma multiforme.’5–11 Primary GBM appears […]
Symptomatic Spinal Metastases from Intracranial High-grade Glioma – Report of Four Cases and Review of the Literature
European Oncology & Haematology, 2011;7(3):179-82 DOI: https://doi.org/10.17925/EOH.2011.07.03.179
Intraspinal (leptomeningeal or intramedullary) metastases from primary intracranial gliomas have been well documented in several clinical and pathological series.1–5 Post-mortem and cytological incidence of meningeal and cerebrospinal fluid (CSF) dissemination of up to 40 % has been demonstrated in these studies. Symptomatic intraspinal metastases in patients with primary intracerebral gliomas occur rarely however – roughly […]
Current Treatment Options in Adult Glioblastoma
US Oncological Disease, 2007;1(2):105-9 DOI: https://doi.org/10.17925/OHR.2007.00.2.105
The purpose of this article is to review the current treatment options for patients with glioblastoma (GBM). The current standard of care involves maximal safe surgical resection followed by concurrent chemotherapy with radiation followed by adjuvant chemotherapy. Although level 1 evidence supports the use of this treatment, GBM remains incurable and most patients will succumb […]
State-of-the-art Therapy for Glioblastoma Multiforme
US Oncological Disease, 2007;1(2):103-4 DOI: https://doi.org/10.17925/OHR.2007.00.2.103
The treatment of patients with glioblastoma multiforme (GBM) is considered to be a palliative venture with no hope of cure. Traditionally, patients are treated with maximal surgical resection based on the premise that, although surgery is not a curative procedure, a major resection leads to longer survival and better quality of life.1 Radiotherapy increases the […]
Current Treatment Strategies for Malignant Gliomas
European Oncological Disease, 2007;1(2):98-9 DOI: https://doi.org/10.17925/EOH.2007.0.2.98
Anaplastic astrocytomas, oligoastrocytomas and oligodendrogliomas (World Health Organization (WHO) grade III) and glioblastomas (WHO grade IV) are collectively referred to as malignant gliomas, whereas WHO grade I and II gliomas are designated low-grade gliomas.1 For decades, neurosurgical resection – whenever possible – and post-operative radiotherapy have been the cornerstones of treatment for malignant gliomas. Most […]
Magnetic Resonance Imaging Findings of Radiation-induced Changes After Treatment of Malignant Gliomas and Metastases with a Particular Emphasis on Radiation Necrosis
European Oncology & Haematology, 2011;7(1):53-58 DOI: https://doi.org/10.17925/EOH.2011.07.01.53
New contrast-enhancing lesions discovered on routine follow-up brain imaging at or near the site of previously treated primary or metastatic brain tumours represent a challenge for radiologists and oncologists, as radiation-induced injuries may have an appearance that is virtually indistinguishable from that of recurrent disease. With standard magnetic resonance imaging (MRI) modalities, a reliable distinction […]
Endocrine Complications in Children Treated for Medulloblastoma or Ependymoma using Radiation Therapy – Outcomes in the Computed Tomography Planning Era
European Oncology & Haematology, 2011;7(1):48-52 DOI: https://doi.org/10.17925/EOH.2011.07.01.48
Radiation therapy as a means to improve outcome for a patient suffering from medulloblastoma was first used by Cushing in the 1920s. In 1953 Patterson and Farr reported their success on 27 medulloblastoma patients treated with craniospinal irradiation.1 As technology has improved, radiation oncologists have developed techniques to deliver higher-energy radiation beams that are more […]
Gliomatosis cerebri type II: two case reports
Introduction Gliomatosis cerebri (GC) is a diffuse, frequently bilateral, glial tumor which infiltrates the brain, involving more than two lobes. It often extends to the infratentorial structures and even to the spinal cord. According to the current WHO classification of brain tumors, GC is a distinct malignant neuroepithelial neoplasm of uncertain origin 1. Pathologists describe […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!